Currently Enrolling

Below is a list of studies that we will either be soon enrolling or that we are currently enrolling for at Mills Clinical Research.

They include studies on and for the following:

  • New HIV medications
  • People looking to switch HIV medications
  • HIV vaccine research
  • Male hormone replacement therapy

Interested? Call 310-550-2271 to speak to the study coordinator.

Currently Enrolling Studies

Male Hormone Replacement Study

AbbVie: Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men.

This study will look at the effects of testosterone replacement therapy (TRT) on major adverse cardiovascular events (MACE).

Functional Cure Study

Sangamo/City of Hope: A pilot study to evaluate the feasibility and safety of CCR5 modified hematopoietic stem/progenitor cells in HIV-positive individuals.

This study is looking at the use of stem cells in treating HIV.

(No longer enrolling.)

Therapeutic Study

Gilead: A Phase 1B randomized, double-blinded, placebo-controlled, multi-cohort study of the safety, pharmacokinetics, and antiviral activity of GS-6207 administered subcutaneously in HIV-1-infected subjects.

This study is looking at the safety and effects of a new long-acting injectable therapy called a “capsid inhibitor” for treatment of HIV.

Therapeutic Study

Trogarzo Study: A Phase 3 study of the safety of Trogarzo™ administered as an undiluted “IV Push” over a reduced interval in clinically-stable HIV-1 infected Trogarzo™ experienced patients.

This study is for a long-acting injectable treatment for HIV that would replace taking daily oral medications.

Upcoming Studies for HIV Treatment

Therapeutic Vaccine Study

Janssen: multi-center, randomized, double-blind Phase 1/2a study evaluating safety, efficacy and immunogenicity of two different vaccine regimens and a TLR7 agonist in HIV-1-infected adults who started antiretroviral treatment during acute HIV infection.

This study will look at the safety and effects of 2 vaccines with a type of treatment called “TLR7 Agonist” that helps the immune system fight HIV.

If you are interested in participating in a study, please give us a call at  310-550-2271.